Yujue Wang

ORCID: 0000-0003-0785-8256
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Immunotherapy and Immune Responses
  • CAR-T cell therapy research
  • Cutaneous Melanoma Detection and Management
  • Histone Deacetylase Inhibitors Research
  • Epigenetics and DNA Methylation
  • Pneumonia and Respiratory Infections
  • RNA modifications and cancer
  • Cancer Cells and Metastasis
  • Vaccine Coverage and Hesitancy
  • Mitochondrial Function and Pathology
  • Blood groups and transfusion
  • Cancer-related molecular mechanisms research
  • Erythrocyte Function and Pathophysiology
  • Melanoma and MAPK Pathways
  • Cancer Immunotherapy and Biomarkers
  • Genomics, phytochemicals, and oxidative stress
  • Cancer Genomics and Diagnostics
  • Microbial Inactivation Methods
  • Genetic and rare skin diseases.
  • Microfluidic and Bio-sensing Technologies
  • Protein Degradation and Inhibitors
  • Radiopharmaceutical Chemistry and Applications
  • RNA Interference and Gene Delivery
  • Coronary Artery Anomalies
  • Invertebrate Immune Response Mechanisms

Rutgers Cancer Institute of New Jersey
2021-2025

Jilin University
2023-2025

Rutgers, The State University of New Jersey
2021-2025

University of Science and Technology Beijing
2025

Johnson University
2021-2025

Sichuan University
2025

Yueyang Hospital
2022-2024

Shanghai University of Traditional Chinese Medicine
2022-2024

National Clinical Research
2024

Suzhou Institute of Biomedical Engineering and Technology
2022-2024

Rationally sequencing and combining PD-1/L1-and MAPK-targeted therapies may overcome innate acquired resistance. Since increased clinical benefit of MAPK inhibitors (MAPKi) is associated with previous immune checkpoint therapy, we compare the efficacies sequential and/or combinatorial regimens in subcutaneous murine models melanoma driven by BrafV600, Nras, or Nf1 mutations as well colorectal pancreatic carcinoma KrasG12C. Anti-PD-1/L1 lead-in preceding MAPKi combination optimizes response...

10.1016/j.ccell.2021.07.023 article EN cc-by-nc-nd Cancer Cell 2021-08-19

Unlike advances in the genomics-driven precision treatment of cutaneous melanomas, current poor understanding molecular basis mucosal melanomas (MM) has hindered such progress for MM patients. Thus, we sought to characterize genomic landscape identify alterations with prognostic and/or therapeutic implications.Whole-genome sequencing (WGS) was performed on 65 samples, including 63 paired tumor blood samples and 2 matched lymph node metastases, a further droplet digital PCR-based validation...

10.1158/1078-0432.ccr-18-3442 article EN Clinical Cancer Research 2019-02-19

Butyrate (B) is a short-chain fatty acid produced by dietary fiber, known to inhibit histone deacetylases (HDACs) and possess cancer-preventive/anticancer effects. However, the role of B in metabolic rewiring, epigenomic reprogramming, transcriptomic network, NRF2 signaling, eliciting cancer-preventive effects colorectal cancer (CRC) HCT116 cell remains unclear.Sodium butyrate (NaB) dose-dependently inhibits growth CRC cells. NaB NRF2/NRF2-target genes blocks NRF2-ARE signaling. increases...

10.1002/mnfr.202200028 article EN Molecular Nutrition & Food Research 2022-04-16

Precancerous lesions of the oral mucosa, especially those accompanied by moderate to severe dysplasia, contribute initiation squamous cell carcinoma (OSCC). However, cellular compositions and spatial organization precancerous stage how these factors promote human OSCC remain unclear. Here, we built a single-cell transcriptome atlas map after obtaining data from pairwise mucosal biopsies 9 individuals consisting very early-stage OSCC, adjacent with as well matched normal region. An altered...

10.1038/s41421-023-00532-4 article EN cc-by Cell Discovery 2023-03-13

Head and neck squamous cell carcinoma (HNSCC) is a common frequently lethal cancer with few therapeutic options. In particular, there are effective targeted therapies. Development of highly strategies tailored to patients HNSCC remains pressing challenge. To address this, we present pharmacogenomic study facilitate precision treatments for HNSCC. We established large collection 56 patient-derived cells (PDCs), which recapitulated the molecular features original tumors. Pharmacological...

10.1126/scitranslmed.abo5987 article EN Science Translational Medicine 2022-09-07

Abstract De novo mutations, a consequence of errors in DNA repair or replication, have been reported to accumulate with age normal tissues humans and model organisms. This accumulation during development aging has implicated as causal factor age-related pathology, including but not limited cancer. Due their generally very low abundance mutations difficult detect tissues. Only recent advances sequencing single-cells, clonal lineages ultra-high-depth small tissue biopsies, somatic mutation...

10.1093/nar/gkab914 article EN Nucleic Acids Research 2021-09-30

Left ventricular hypertrophy leads to heart failure, a serious medical condition associated with high rates of hospitalization and mortality. Limited success the existing pharmacological treatments necessitates development mechanisms-based new therapies better control progression from left failure. The current work investigated potentials mechanisms naturally occurring cinnamic acid in treatment vitro findings reveal that attenuates hypertrophic responses mitochondrial dysfunction...

10.1016/j.biopha.2023.115168 article EN Biomedicine & Pharmacotherapy 2023-07-13

Abstract Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous environmental carcinogens accountable to developing skin cancers. Recently, we reported that exposure benzo[a]pyrene (B[a]P), a common PAH, causes epigenetic and metabolic alterations in the initiation, promotion progression of non-melanoma cancer (NMSC). As follow-up investigation, this study examines how dietary triterpenoid ursolic acid (UA) regulates B[a]P-driven pathways SKH-1 hairless mice. Our results show UA intercepts...

10.1093/carcin/bgae009 article EN Carcinogenesis 2024-03-11

Ursolic acid (UA) is a triterpenoid phytochemical with strong anticancer effect. The metabolic rewiring, epigenetic reprogramming, and chemopreventive effect of UA in prostate cancer (PCa) remain unknown. Herein, we investigated the efficacy PCa xenograft, its biological effects on cellular metabolism, DNA methylation, transcriptomic using multi-omics approaches. metabolomics was quantified by liquid-chromatography-mass spectrometry (LC-MS) while epigenomic CpG methylation parallel gene...

10.1002/mc.23365 article EN Molecular Carcinogenesis 2021-11-02

Abstract Cetuximab is a widely used drug for treating head and neck squamous cell carcinomas (HNSCCs); however, it provides restricted clinical benefits, its response duration limited by resistance. Here, we conducted randomized “Phase II-like trials” of 49 HNSCC PDX models reveal multiple informative biomarkers intrinsic resistance to cetuximab (e.g., amplification ANKH , up-regulation PARP3). After validating these in another cohort (61 models), generated acquired analyzed them uncover...

10.1038/s41392-022-00908-0 article EN cc-by Signal Transduction and Targeted Therapy 2022-03-08

Indole-3-carbinol (I3C) is shown to possess multiple pharmacological activities such as anti-inflammatory, antimicrobial, antioxidant, antiviral, and anti-cancer activities. It widely accepted modulator of signaling pathways particularly those related cell cycle, growth division, angiogenesis, apoptosis immunity. We explored the metabolic reprogramming based on treatment with I3C in mice prostate tissue. In this study we utilized Pten knockout (KO)-induced tumorigenesis mouse model examine...

10.1007/s11095-025-03820-8 article EN cc-by Pharmaceutical Research 2025-02-01

For solid tumors, hypoxia is associated with disease aggressiveness and poor outcomes. In addition to undergoing broad intracellular molecular metabolic adaptations, hypoxic tumor cells extensively communicate their microenvironments facilitate conditions favorable for survival, growth, metastasis. This communication mediated by diverse secretory factors, including exosomes (extracellular vesicles of endosomal origin). Exosomal cargo altered considerably hypoxia, significant impacts on...

10.1038/s41598-025-97488-0 article EN cc-by-nc-nd Scientific Reports 2025-04-16

Pre-eclampsia (PE) is a pregnancy disorder that characterised by severe hypertension and increased risks of foetal maternal mortality. The aetiology PE not completely understood; however, nutrition oxidative stress play important roles in the development hypertension. treatment options for are currently limited to anti-hypertensive drugs. Punicalagin, polyphenol present pomegranate juice, has range bioactive properties. effects supplementation with punicalagin on angiogenesis pregnant rats...

10.4196/kjpp.2018.22.4.409 article EN Korean Journal of Physiology and Pharmacology 2018-01-01

Abstract Non-melanoma skin cancer (NMSC) is the most common in world. Environmental exposure to carcinogens one of major causes NMSC initiation and progression. In current study, we utilized a two-stage carcinogenesis mouse model generated by sequential cancer-initiating agent benzo[a]pyrene (BaP) promoting 12-O-tetradecanoylphorbol-13-acetate (TPA), study epigenetic, transcriptomic metabolic changes at different stages during development NMSC. BaP/TPA caused significant alterations DNA...

10.1093/carcin/bgad024 article EN Carcinogenesis 2023-04-26

Abstract Kirsten rat sarcoma virus (KRAS) oncogene, found in 20%–25% of lung cancer patients, potentially regulates metabolic reprogramming and redox status during tumorigenesis. Histone deacetylase (HDAC) inhibitors have been investigated for treating KRAS‐mutant cancer. In the current study, we investigate effect HDAC inhibitor (HDACi) belinostat at clinically relevant concentration on nuclear factor erythroid 2‐related 2 (NRF2) mitochondrial metabolism treatment human LC‐MS metabolomic...

10.1002/mc.23551 article EN Molecular Carcinogenesis 2023-05-05

Mechanosensitive PIEZO2 ion channels play roles in touch, proprioception, and inflammatory pain. Currently, there are no small molecule inhibitors that selectively inhibit over PIEZO1. The TMEM120A protein was shown to while leaving PIEZO1 unaffected. Here we find expression elevates cellular levels of phosphatidic acid lysophosphatidic (LPA), aligning with its structural resemblance lipid-modifying enzymes. Intracellular application or LPA inhibited PIEZO2, but not activity. Extended...

10.1101/2024.03.01.582964 preprint EN cc-by-nc-nd bioRxiv (Cold Spring Harbor Laboratory) 2024-03-02

Mechanosensitive PIEZO2 ion channels play roles in touch, proprioception, and inflammatory pain. Currently, there are no small molecule inhibitors that selectively inhibit over PIEZO1. The TMEM120A protein was shown to while leaving PIEZO1 unaffected. Here we find expression elevates cellular levels of phosphatidic acid lysophosphatidic (LPA), aligning with its structural resemblance lipid-modifying enzymes. Intracellular application or LPA inhibits but not activity. Extended extracellular...

10.1038/s41467-024-51181-4 article EN cc-by-nc-nd Nature Communications 2024-08-15

Accelerated brain aging, i.e., the age-related structural changes in appearing earlier than expected from one's chronological age, is a feature that now well established schizophrenia. Often interpreted as of progressive pathophysiological process typifies schizophrenia, its prognostic relevance still unclear. We investigate role response to antipsychotic treatment first-episode

10.1177/07067437241293981 article EN cc-by The Canadian Journal of Psychiatry 2024-11-10

Herein, we report a new series of bifunctional chelators (BFCs) with high affinity for amyloid aggregates, strong binding toward Cu(II), and favorable lipophilicity potential blood–brain barrier penetration. The alkyl carboxylate ester pendant arms offer up to 3 orders magnitude higher Cu(II) enable the BFCs form stable 64Cu-radiolabeled complexes. Among five compounds tested, 64Cu-YW-7 64Cu-YW-10 complexes exhibit specific staining plaques in ex vivo autoradiography studies. Importantly,...

10.1021/acs.inorgchem.1c02079 article EN Inorganic Chemistry 2021-08-05
Coming Soon ...